Do analysts prefer IRD or ICCC?

Opus Genetics presently has a consensus target price of $10.77, suggesting a potential upside of 190.28%. Given Opus Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Opus Genetics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 2.94 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, IRD or ICCC?

ImmuCell has higher revenue and earnings than Opus Genetics. ImmuCell is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 21.57 -$49.59M -$1.33 N/A ImmuCell $27.64M 3.21 -$1.04M -$0.06 N/A

Is IRD or ICCC more profitable?

ImmuCell has a net margin of -1.82% compared to Opus Genetics' net margin of -892.36%. ImmuCell's return on equity of -1.88% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -892.36% -338.88% -191.21% ImmuCell -1.82% -1.88% -1.22%

Does the media favor IRD or ICCC?

In the previous week, Opus Genetics had 1 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Opus Genetics and 3 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.14 beat Opus Genetics' score of 0.17 indicating that ImmuCell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ICCC or UPB?

Upstream Bio has a consensus price target of $33.17, indicating a potential upside of 421.08%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has higher earnings and valuation, ICCC or UPB?

ImmuCell has higher revenue and earnings than Upstream Bio. ImmuCell is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.21 -$1.04M -$0.06 N/A Upstream Bio $2.85M 121.54 -$143.44M -$2.91 N/A

Is ICCC or UPB more profitable?

ImmuCell has a net margin of -1.82% compared to Upstream Bio's net margin of -4,718.96%. ImmuCell's return on equity of -1.88% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Upstream Bio -4,718.96% -43.82% -42.27%

Does the media refer more to ICCC or UPB?

In the previous week, ImmuCell and ImmuCell both had 3 articles in the media. ImmuCell's average media sentiment score of 1.14 beat Upstream Bio's score of 0.52 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts rate NVCT or ICCC?

Nuvectis Pharma currently has a consensus price target of $39.00, suggesting a potential upside of 59.31%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvectis Pharma is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer NVCT or ICCC?

In the previous week, Nuvectis Pharma had 6 more articles in the media than ImmuCell. MarketBeat recorded 9 mentions for Nuvectis Pharma and 3 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.14 beat Nuvectis Pharma's score of 0.75 indicating that ImmuCell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AMRN or ICCC?

Amarin presently has a consensus target price of $12.00, indicating a potential downside of 26.95%. Given Amarin's stronger consensus rating and higher probable upside, equities analysts plainly believe Amarin is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.00 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, AMRN or ICCC?

ImmuCell has lower revenue, but higher earnings than Amarin. ImmuCell is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.61 -$38.80M -$0.65 N/A ImmuCell $27.64M 3.21 -$1.04M -$0.06 N/A

Is AMRN or ICCC more profitable?

ImmuCell has a net margin of -1.82% compared to Amarin's net margin of -15.51%. ImmuCell's return on equity of -1.88% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% ImmuCell -1.82% -1.88% -1.22%

Do analysts rate ABEO or ICCC?

Abeona Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 238.08%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Abeona Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

ImmuCell (ICCC) Competitors

$9.79 -0.07 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$9.76 -0.03 (-0.31%)

As of 04:10 PM Eastern

Compare

ICCC vs. IRD, UPB, NVCT, AMRN, and ABEO

Should you buy ImmuCell stock or one of its competitors? MarketBeat compares ImmuCell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmuCell include Opus Genetics (IRD), Upstream Bio (UPB), Nuvectis Pharma (NVCT), Amarin (AMRN), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry.

How does ImmuCell compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

ImmuCell has a net margin of -1.82% compared to Opus Genetics' net margin of -892.36%. ImmuCell's return on equity of -1.88% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
ImmuCell	-1.82%	-1.88%	-1.22%

In the previous week, Opus Genetics had 1 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Opus Genetics and 3 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.14 beat Opus Genetics' score of 0.17 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has higher revenue and earnings than Opus Genetics. ImmuCell is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.57	-$49.59M	-$1.33	N/A
ImmuCell	$27.64M	3.21	-$1.04M	-$0.06	N/A

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Opus Genetics presently has a consensus target price of $10.77, suggesting a potential upside of 190.28%. Given Opus Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Opus Genetics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Opus Genetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Summary

Opus Genetics beats ImmuCell on 9 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Upstream Bio?

ImmuCell (NASDAQ:ICCC) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

ImmuCell has higher revenue and earnings than Upstream Bio. ImmuCell is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.21	-$1.04M	-$0.06	N/A
Upstream Bio	$2.85M	121.54	-$143.44M	-$2.91	N/A

ImmuCell has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

13.5% of ImmuCell shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ImmuCell and ImmuCell both had 3 articles in the media. ImmuCell's average media sentiment score of 1.14 beat Upstream Bio's score of 0.52 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Upstream Bio has a consensus price target of $33.17, indicating a potential upside of 421.08%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

ImmuCell has a net margin of -1.82% compared to Upstream Bio's net margin of -4,718.96%. ImmuCell's return on equity of -1.88% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Summary

ImmuCell beats Upstream Bio on 8 of the 14 factors compared between the two stocks.

How does ImmuCell compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Nuvectis Pharma had 6 more articles in the media than ImmuCell. MarketBeat recorded 9 mentions for Nuvectis Pharma and 3 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.14 beat Nuvectis Pharma's score of 0.75 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvectis Pharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
ImmuCell	-1.82%	-1.88%	-1.22%

ImmuCell has higher revenue and earnings than Nuvectis Pharma. ImmuCell is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
ImmuCell	$27.64M	3.21	-$1.04M	-$0.06	N/A

Nuvectis Pharma currently has a consensus price target of $39.00, suggesting a potential upside of 59.31%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvectis Pharma is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nuvectis Pharma and ImmuCell tied by winning 7 of the 14 factors compared between the two stocks.

How does ImmuCell compare to Amarin?

Amarin (NASDAQ:AMRN) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Amarin presently has a consensus target price of $12.00, indicating a potential downside of 26.95%. Given Amarin's stronger consensus rating and higher probable upside, equities analysts plainly believe Amarin is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has lower revenue, but higher earnings than Amarin. ImmuCell is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.61	-$38.80M	-$0.65	N/A
ImmuCell	$27.64M	3.21	-$1.04M	-$0.06	N/A

In the previous week, Amarin had 13 more articles in the media than ImmuCell. MarketBeat recorded 16 mentions for Amarin and 3 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.14 beat Amarin's score of 0.56 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Positive
ImmuCell	Positive

ImmuCell has a net margin of -1.82% compared to Amarin's net margin of -15.51%. ImmuCell's return on equity of -1.88% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
ImmuCell	-1.82%	-1.88%	-1.22%

Amarin has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

ImmuCell beats Amarin on 8 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, ImmuCell had 3 more articles in the media than Abeona Therapeutics. MarketBeat recorded 3 mentions for ImmuCell and 0 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.90 beat ImmuCell's score of 1.14 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Abeona Therapeutics	Very Positive
ImmuCell	Positive

Abeona Therapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
ImmuCell	-1.82%	-1.88%	-1.22%

Abeona Therapeutics has higher earnings, but lower revenue than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	55.03	$71.18M	$0.97	5.79
ImmuCell	$27.64M	3.21	-$1.04M	-$0.06	N/A

Abeona Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Abeona Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 238.08%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Abeona Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Abeona Therapeutics beats ImmuCell on 11 of the 15 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCC vs. The Competition

Export

Metric	ImmuCell	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$89.25M	$8.18B	$6.56B	$12.24B
Dividend Yield	N/A	2.59%	2.69%	5.82%
P/E Ratio	N/A	15.21	25.17	23.98
Price / Sales	3.21	5.89	553.76	120.62
Price / Cash	51.17	16.83	44.82	54.51
Price / Book	3.27	3.29	10.76	6.41
Net Income	-$1.04M	$226.25M	$3.56B	$337.14M
7 Day Performance	4.26%	-0.96%	1.37%	-0.48%
1 Month Performance	-3.26%	-2.77%	0.81%	0.49%
1 Year Performance	42.30%	0.16%	30.53%	28.16%

ImmuCell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCC ImmuCell	1.5393 of 5 stars	$9.79 -0.7%	N/A	+48.3%	$89.25M	$27.64M	N/A	70	News Coverage Positive News
IRD Opus Genetics	2.8441 of 5 stars	$4.06 +4.1%	$10.67 +162.7%	+350.2%	$335.22M	$11.98M	N/A	14	Analyst Forecast
UPB Upstream Bio	2.088 of 5 stars	$6.15 +3.9%	$33.17 +439.3%	-41.0%	$334.68M	$2.85M	N/A	38	News Coverage
NVCT Nuvectis Pharma	2.2675 of 5 stars	$12.59 +5.4%	$13.00 +3.3%	+120.5%	$334.01M	N/A	N/A	8	News Coverage Analyst Forecast
AMRN Amarin	1.1736 of 5 stars	$15.77 +4.0%	$12.00 -23.9%	+26.7%	$330.68M	$216.76M	N/A	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuCell (ICCC) Competitors

ICCC vs. IRD, UPB, NVCT, AMRN, and ABEO

How does ImmuCell compare to Opus Genetics?

Summary

How does ImmuCell compare to Upstream Bio?

Summary

How does ImmuCell compare to Nuvectis Pharma?

Summary

How does ImmuCell compare to Amarin?

Summary

How does ImmuCell compare to Abeona Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuCell (ICCC) Competitors

ICCC vs. IRD, UPB, NVCT, AMRN, and ABEO

How does ImmuCell compare to Opus Genetics?

Is IRD or ICCC more profitable?

Does the media favor IRD or ICCC?

Which has stronger earnings & valuation, IRD or ICCC?

Do institutionals & insiders have more ownership in IRD or ICCC?

Do analysts prefer IRD or ICCC?

Which has more volatility & risk, IRD or ICCC?

Summary

How does ImmuCell compare to Upstream Bio?

Which has higher earnings and valuation, ICCC or UPB?

Which has more volatility & risk, ICCC or UPB?

Do institutionals and insiders believe in ICCC or UPB?

Does the media refer more to ICCC or UPB?

Do analysts recommend ICCC or UPB?

Is ICCC or UPB more profitable?

Summary

How does ImmuCell compare to Nuvectis Pharma?

Does the media prefer NVCT or ICCC?

Do institutionals & insiders hold more shares of NVCT or ICCC?

Which has more volatility & risk, NVCT or ICCC?

Is NVCT or ICCC more profitable?

Which has better earnings & valuation, NVCT or ICCC?

Do analysts rate NVCT or ICCC?

Summary

How does ImmuCell compare to Amarin?

Do analysts recommend AMRN or ICCC?

Which has preferable earnings and valuation, AMRN or ICCC?

Does the media favor AMRN or ICCC?

Is AMRN or ICCC more profitable?

Which has more volatility & risk, AMRN or ICCC?

Do institutionals and insiders have more ownership in AMRN or ICCC?

Summary

How does ImmuCell compare to Abeona Therapeutics?

Does the media prefer ABEO or ICCC?

Is ABEO or ICCC more profitable?

Which has stronger valuation & earnings, ABEO or ICCC?

Which has more risk & volatility, ABEO or ICCC?

Do analysts rate ABEO or ICCC?

Do institutionals & insiders believe in ABEO or ICCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools